Skip to main content
. Author manuscript; available in PMC: 2011 Sep 16.
Published in final edited form as: J Acquir Immune Defic Syndr. 2010 Jul;54(3):258–268. doi: 10.1097/QAI.0b013e3181d0db97

Figure A2. 20-year survival, by type of monitoring strategy.

Figure A2

This figure depicts time (x-axis) and survivorship (y-axis) for a treatment-eligible cohort entering care with mean CD4 140 cells/μL (standard deviation 116 cells/μL) for patients relying on clinical- (small dashed line), CD4- (solid line), or HIV RNA- (large dashed line) based switching strategies. Median survivals, indicated by the dotted line, were 12.79, 16.13, and 18.96 years, respectively. At approximately 2 years, the proportion of the initial cohort surviving and receiving HIV RNA monitoring began to diverge from the proportion of the cohort surviving and receiving clinical and CD4 count monitoring. By 5 years, the proportion of the initial cohort surviving and receiving CD4 count monitoring diverged from the proportion of the initial cohort surviving and receiving clinical monitoring.